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SHORT COMMUNICATION
Antimicrobial activity, synergism and inhibition of germ tube formation
by Crocus sativus-derived compounds against Candida spp.
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Abstract
The limited arsenal of synthetic antifungal agents and the emergence of resistant Candida
strains have prompted the researchers towards the investigation of naturally occurring
compounds or their semisynthetic derivatives in order to propose new innovative hit
compounds or new antifungal combinations endowed with reduced toxicity. We explored the
anti-Candida effects, for the first time, of two bioactive compounds from Crocus sativus stigmas,
namely crocin 1 and safranal, and some semisynthetic derivatives of safranal obtaining
promising biological results in terms of minimum inhibitory concentration/minimum fungicidal
concentration (MIC/MFC) values, synergism and reduction in the germ tube formation. Safranal
and its thiosemicarbazone derivative 5 were shown to display good activity against Candida
spp.
Keywords
Candida spp., checkerboard method, Crocus
sativus L., germ tube formation, safranal
History
Received 29 March 2016
Revised 15 April 2016
Accepted 17 April 2016
Published online 3 May 2016
Introduction
Candida albicans, a dimorphic opportunistic human pathogen, is
the most prominent cause of oropharyngeal or invasive candid-
iasis in man1. In particular, oropharyngeal infections are very
common in HIV-infected individuals and patients with AIDS,
while deep-seated infections are frequent in neutropenic patients2.
The incidence of candidiasis has dramatically increased in the last
decades and bloodstream infections due to Candida spp. are
becoming a prime cause of morbidity and mortality in different
types of immunocompromised patients3. Among the numerous
factors associated with virulence in C. albicans, hyphal morpho-
genesis is likely to be one of the most important4. Hyphae
development from yeast cells is critical for adherence, an essential
first step in microbial colonization, which is in turn a key event in
the initiation of the pathogenic process5. Different classes of
antimycotic drugs are available to treat fungal infections. Azoles
remain among the most common antifungal drugs, but their
intensive clinical use for both therapy and prophylaxis has
favoured the emergence of resistant strains6. The echinocandins
were cytolytic drugs which inhibit cell wall synthesis through the
blockage of 1,3-b-glucan synthase and have rapidly become an
important therapeutic option in several fungal infections7.
Although echinocandin resistance is still considered unusual,
cases of resistance by using this therapeutic class have become
increasingly frequent8. Echinocandins display predominantly
fungicidal activity against Candida spp.9. The main resistance
mechanism described for echinocandins involves the occurrence
of mutations in the FKS1 gene, resulting in conformational
changes in the enzyme encoded by this gene (Fks1), decreased
affinity between echinocandins and Fks1, and the consequent
inefficacy of these compounds10.
The threat of increasing antifungal resistance (ADR) asso-
ciated with the relative scarcity of antifungal drugs prompted the
development of new compounds. To resolve this emergence,
alternatives to conventional antimicrobial therapy and synergism
among different classes of antifungal agents have been explored
by our research group11–17. The concept of antimicrobial synergy
is based on the principle that, in combination with other drugs, the
formulation may enhance efficacy, reduce toxicity, decrease
adverse side effects, increase bioavailability, lower the dose and
reduce the development of antimicrobial resistance18. Synergism
between antimicrobial drugs and compounds of natural origin19
was generally performed in many studies, but only few reported it
among substances of natural origin20.
Moreover, we also focused our efforts on the biological
characterization of bioactive compounds from the dried stigma of
Crocus sativus L., keeping in mind the importance of screening
naturally occurring products for the treatment of fungal infec-
tions21. This expensive spice (saffron), belonging to the Iridaceae
family, has been used as a drug in folk medicine since ancient
times for various pharmacological purposes and as colouring
agent22. The presence of carbohydrates, minerals, mucilages,
vitamins and pigments (including anthocyanins, carotenoides,
lycopene, zigzantin and flavonoids) has been reported in saffron
stigmas, among which, crocins, picrocrocin, crocetin and safranal
are regarded as the main active ingredients23. In this study, for the
first time, we aimed at analysing the antifungal activity of some
important bioactive components of saffron, namely crocin 1 (1)
and safranal (2), together with few semisynthetic derivatives (3–9)
of safranal in order to explore the chemical space around the
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carbonylic group of this molecule and to derive structure–activity
relationship (SAR) within this small library (Figure 1).
Materials and methods
Chemistry
Commercial samples of crocin 1 (crocetin digentiobiose ester)
and safranal (88%) were purchased from Sigma-Aldrich (Milan,
Italy). Safranal was further purified by column chromatography
on silica gel (230–400 mesh, G60 Merck, ethyl acetate:n-hexane
1:3). The other compounds (3–9) have been synthesized and
characterized to ensure purity as reported in the literature24,25.
Organisms and growth conditions
The strains used in this study were as follows: 11 strains of
Candida albicans, seven of Candida glabrata, two of Candida
krusei and two of Candida tropicalis. Many of these clinical
isolates showed high resistance towards fluconazole. Fungi were
grown in Sabouraud dextrose agar (SDA) at an optimal growth
temperature of 30–37 C with aeration for 24 h.
Antimicrobial assay: MIC and MFC
The minimum inhibitory concentration (MIC) was determined by
microbroth dilution method (microsterile plate) according to the
National Committee for Clinical Laboratory Standards (NCCLS)
Approved Standard M27-A3, 200826. The Minimum Inhibitory
Concentration (MIC) was determined as the lowest concentration
of compounds at which no microbial growth was observed.
Compounds 1–9 were prepared by dissolution in DMSO.
8 mg/mL solutions of each compound were prepared in RPMI
1640. Briefly, to determine the MIC of test compounds, RPMI-
1640 supplemented with MOPS at pH 7 was used. Test
compounds were diluted in RPMI-1640 supplemented with
Tween 80 (final concentration of 0.001% v/v). The dilutions of
compounds, ranging from 0.0078 to 8 mg/mL, were prepared in
96-well plates. The inoculum size was about 2.5 103 cells/mL.
The plates were incubated at 30 C for 48 h. To determine the
minimum fungicidal concentration (MFC), Sabouraud dextrose
agar (SDA) plates were seeded with 10 mL cell suspensions taken
from the wells of the MIC assay plates where cell growth was not
observed. These plates were incubated at 30 C for 48 h and
colony-forming units (CFU) growth was evaluated.
Checkerboard method used to evaluate the synergic
action of compounds
Twelve serial twofold dilutions of 2 and 5 were prepared
following the same broth dilution method adopted to assess
MICs. A dilution of 2 and 5 was prepared ranging from 0.0078 to
8 mg/mL. All 2 and 5 dilutions were mixed with the appropriate
concentration of drug (micafungin, MCFG) or the other com-
pound, thus obtaining a series of different solutions. The analysis
of the combination of the substances was carried out calculating
the fractional inhibitory concentration (FIC) index. The FIC index
(FICI) was calculated dividing the MIC of the combination of
compound and the antifungal reference drug by the MIC of
compound or antifungal reference drug alone:
FIC of compound¼MIC of compound in combination with
antifungal drugs/MIC of compound alone;
FIC of antifungal drug¼MIC of antifungal in combination
with compound/MIC of antifungal drug;
FICI¼ FIC of compound + FIC of antifungal drug.
The FICI, obtained by adding both FICs, was interpreted as
indicating a synergistic effect when it was0.5, as additive or
indifferent when it was 40.5 and 2, and as antagonistic when it
was4227,28.
Germ tube formation
The induction of germ tube formation was conducted by a
preculture in 50 mL of Winge broth at 28 C for 24 h29.
Subsequently, the cells were recovered and resuspended in 5 mL
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Figure 1. Structures of crocin 1 (1), safranal (2) and semisynthetic derivatives (3–9) of safranal.
2 S. Carradori et al. J Enzyme Inhib Med Chem, Early Online: 1–5
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of RPMI supplemented with serum (10% v/v) at O.D. 0.35 nm in
the absence or in the presence of 2 or 5 at concentrations from
0.0039 mg/mL to 1 mg/mL and incubated with agitation to 37 C.
After 0, 90 min, 240 min and 24 h, an aliquot of cells was taken
and counted with a phase contrast microscope using a 40x
objective. The inhibition rate of hyphae formation was obtained
by the ratio between the number of germ tubes observed in
presence of compound 2 or 5 and with those found in the control
without 2 or 5. The number of germ tubes was evaluated using a
Thoma camera.
Results and discussion
Antimicrobial activity of Crocus sativus-derived com-
pounds against Candida spp.
Antimicrobial activity of nine (natural and semisynthetic) com-
pounds: compounds 1–9 against a sensitive strain CO23 of
Candida albicans were tested. Table 1 shows that only safranal (2)
and 5 (thiosemicarbazone derivative of safranal) were active
against C. albicans with MIC values of 1 mg/mL, whereas other
compounds (crocin 1, 3, 4, 6, 7 and 8) showed MIC values
48 mg/mL. Similar values to MICs for fungicidal activity (MFC)
were reported. To confirm the obtained antifungal activity,
safranal (2) and 5 were also tested against 22 strains of
Candida spp. as reported in Table 2. Safranal was more active
than its thiosemicarbazone derivative 5 with MIC50, MIC90, and
MFC values between 1 and 2 mg/mL for all Candida spp. In
particular, C. krusei was more sensitive to safranal with MICs and
MFC values of 1 mg/mL. Conversely, compound 5 was less active
with values between 1 and 8 mg/mL. In many cases, compound 5
was not fungicidal.
At present, the antifungal activity of saffron on C. albicans
was only reported by C.-J. Zheng et al.30, who studied the
inhibitory activity of ethanol extracts constituted with many
compounds and the values of MICs were lower when compared
with ours. Conversely, in this study, for the first time, the
antimicrobial activity has been evaluated with two bioactive
single compounds, so the values of MIC are higher, confirming a
synergistic effect among Crocus sativus constituents.
The fractional inhibitory concentration index (FICI)
To explore the possibility of developing a more powerful
combination therapy of safranal and its derivative 5 together or
with micafungin (MCFG), the checkerboard microtitre test was
performed. Table 3 shows the results obtained in terms of the
minimal inhibitory concentration (MIC). By treatment with
safranal or 5, inhibition of the growth of C. albicans was
achieved at 1 and 2 mg/mL, respectively. In comparison, the MIC
of MCFG was 4mg/mL.
The FICIs calculated from the results of the checkerboard
microtiter assays (Table 3) revealed the following: treating
C. albicans in combination with safranal and its derivative 5
caused a significant decrease in the MIC, compared to their
individual MIC values. For example, the MIC of safranal alone
against C. albicans was lowered from 2 to 0.25 (mg/mL) in the
presence of 5. The MIC of 5 alone also decreased from 4 to
1 (mg/mL). Synergistic effects were obtained only using various
combinations of safranal and 5. Nevertheless, the results indicated
that only an additive effect was obtained with the combination of
safranal or 5 with MCFG. These results are in agreement with
other authors that reported the synergistic effect of three essential
oils against Pseudomonas syringae pv. actinidiae20.
Inhibition of germ tube formation in presence of safranal
or compound 5 in C. albicans
Hyphal growth is an intriguing morphological feature of Candida
albicans and represents an important virulence factor that
contributes to the forming biofilm. The inhibition of germ tube
formation against six strains of C. albicans in the presence of
different safranal or 5 concentrations was evaluated at several
Table 2. Antifungal activity (mg/mL) of safranal (2) and its derivative 5 against twenty-two clinical isolates of Candida spp.
Safranal (2) 5
Candida spp. (n strains) MIC50 MIC90 MFC50 MFC90 MIC50 MIC90 MFC50 MFC90
C. albicans (11) 2 2 2 2 1 4 1 44
C. glabrata (7) 1 2 1 2 4 4 48 48
C. krusei (2) 1 1 1 1 1 1 8 8
C. tropicalis (2) 1 1 1 2 2 2 48 48
MFC50 and MFC90: minimum fungicidal concentration of 50 and 90% of the strains.
Table 3. Fractional inhibitory concentrations (FICs) and indices (FICIs)
of antifungal drug Micafungin (MCFG) combined with safranal and its
thiosemicarbazone derivative 5 against Candida albicans.
MICa MICc FIC FICI
Safranal-Micafungin
Safranal (mg/mL) 1 1 1 1.25
Micafungin (mg/mL) 4 1 0.250
Compound 5-Micafungin
Compound 5 (mg/mL) 2 2 1 1.50
Micafungin (mg/mL) 4 2 0.5
Safranal–Compound 5
Safranal (mg/mL) 2 0.25 0.125 0.375
Compound 5 (mg/mL) 4 1 0.250
MICa: MIC of the sample alone; MICc: MIC of the sample of the most
effective combination. FIC of compound¼MIC of compound in
combination with antifungal drugs/MIC of compound alone. FIC of
antifungal drug¼MIC of antifungal in combination with compound/
MIC of antifungal drug. FICI¼ FIC compound + FIC of antifungal
drug.
Table 1. Antimicrobial activity of test compounds against Candida
albicans.
Compound MIC (mg/mL) MFC (mg/mL)
Crocin 1 (1) 48 48
Safranal (2) 1 4
3 48 48
4 48 48
5 1 1
6 48 48
7 48 48
8 48 48
9 48 48
MIC: minimum inhibitory concentration; MFC: minimum fungicidal
concentration.
DOI: 10.1080/14756366.2016.1180596 Antifungal activity by C. sativus-derived compounds against Candida spp. 3
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time intervals. As the production of germ tubes usually requires
3 h of incubation, it would not be correct to assume that the
inhibition of germ tube formation occurred at 90 min, but the
experiment clearly demonstrated that this event is inhibited at an
early stage of transition at least 90 min after the onset of
incubation. Nevertheless, it has been confirmed the inhibition
until 24 h. It is noteworthy that germ tube inhibition occurred at
the subinhibitory concentration as reported in Table 4. In
particular, after 24 h of induction, safranal (2) was found to
inhibit hyphae formation at a rate about 41.52 ± 15.60% at a
concentration of 0.0312 mg/mL and completely at a concentration
of 0.0625 mg/mL equal to 1/32 MIC. At the same concentrations
of safranal (2), derivative 5 was found to inhibit hyphae formation
about 19.0 ± 9.9 and 10.7 ± 3.88, respectively. The total inhibition
was obtained at concentration of 0.125 mg/mL also in this case,
corresponding to 1/32 MIC. Values of SD reported in Table 4
were sometimes higher than value of means, but this discrepancy
strongly depends on hyphae that make heaps and can be counted
difficultly.
The literature includes many studies assessing the susceptibil-
ity of yeasts of the genus Candida to medicinal plant derivatives;
however, few studies have investigated the plant derivatives’
effects on C. albicans morphology and germ tube formation31.
According to Silva et al.32, a compound’s ability to inhibit germ
tube formation could be a means to assess its antifungal activity.
The ability to reduce yeast viability is a desired quality in
candidate products and/or compounds that could be developed
into novel therapeutic agents.
SAR studies on naturally occurring and semisynthetic
derivatives as antifungal agents
Collectively, crocin 1 was not active as antifungal agent
(MIC48 mg/mL), whereas the most important component of the
volatile fraction of saffron (safranal) displayed a promising
inhibitory activity against the selected Candida albicans strain.
Among its semisynthetic derivatives, obtained by transformation
of the carbonylic function into semicarbazone (3) and (sub-
stituted) thiosemicarbazone derivatives (4–6), only the thiosemi-
carbazone 5 was endowed with the same MIC value and a lower
MFC value. The successive cyclization of the thioamidic portion
of compound 5 led to inactive derivatives (thiazolidinones (7 and
8) and thiazole (9)), suggesting a pivotal role for this moiety. This
is confirmed by several studies in the literature showing that
thiosemicarbazone derivatives usually act as potent anti-Candida
agents11–17. In detail, researchers focused their attention on the
effect of these compounds as potent iron chelators and as selective
inhibitors of dihydrofolate reductase (DHFR) of Candida
albicans36,37. For these reasons, compound 5 was further explored
along with its parent compound safranal against twenty-two
clinical isolates of Candida spp. and for the determination of their
FIC index and inhibition of germ tube formation.
Conclusion
The urgency of new compounds with anti-Candida activity has
increased due to the therapeutic failure, fast development of
resistant strains and low bioavailability of current drugs.
Moreover, the correct evaluation of the efficacy of a new
antifungal compound requires several in vitro assays such as MIC/
MFC determination, combination therapy and inhibition of Germ
Tube formation. We performed, for the first time, this large
biological screening for two bioactive compounds of Crocus
sativus L. (crocin 1 and safranal) and modified the chemical
structure of safranal to obtain some semisynthetic derivatives. In
conclusion, the obtained results show an interesting antifungal
activity of safranal against Candida spp. and a synergistic effect
when used in combination with derivative 5. Finally, these two
bioactive compounds were able to inhibit completely germ tube
formation, an important virulence factor in C. albicans, at
concentration of 1/32 MIC. Some chemical modifications yielded
more potent and promising compounds, which could be used as
lead compounds for the search of innovative anti-Candida agents.
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